OVX033 / Osivax - LARVOL DELTA

Phase 1, first-in-human, randomized, placebo-controlled, dose-escalating study to evaluate OVX033, a nucleocapsid-based SARS-CoV-2 candidate vaccine. (PubMed, J Infect Dis) - "OVX033 demonstrated a favorable safety profile and strong boosting of pre-existing N-specific humoral immunity. Although a N-specific T-cell-mediated immune response was achieved, it remained of limited amplitude. This limitation could be addressed by implementing a two-dose regimen, or through the adjuvantation of the vaccine."

First-in-human • Journal • P1 data • Fatigue • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Pain • Respiratory Diseases • CD4 • CD8 • IFNG

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Osivax | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

OVX033, N-based T-cell broad-spectrum vaccine candidate against all sarbecovirus is safe and immunogenic in non-human primates (ISIRV-OPTIONS XII 2024) - No abstract available

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: Osivax | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Osivax | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Osivax

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease